Should You Repeat Molecular Testing — After Your Cancer Progresses?

For some purposes, yes — and for others, no. A liquid biopsy detects cell-free tumour DNA circulating in the blood and can identify resistance mutations without a surgical procedure. For certain cancer types and specific mutations, the sensitivity is high enough to guide treatment. For others, a negative liquid biopsy still leads to a tissue biopsy to confirm, because missing the mutation on blood alone would be the wrong basis for a decision. Your oncologist will tell you whether liquid biopsy is validated for your cancer type at this stage, or whether tissue remains the standard. If tissue biopsy carries significant procedural risk, liquid biopsy is often the preferred first step rather than an afterthought.

The most straightforward option is a new biopsy from a site of active progression — ideally a site that has grown or appeared since the last scan, because that tissue is most likely to reflect the current molecular profile. If biopsy carries significant procedural risk, liquid biopsy is the alternative. In some cases, archived material from a different time point — an older surgical specimen, for instance — can be retrieved and tested, though it may not reflect how the disease has evolved since. Ask your oncologist which site is safest to biopsy and whether a liquid biopsy is a reasonable substitute for your particular cancer type and the specific question being asked.

Standard tissue-based next-generation sequencing typically takes one to two weeks from when the laboratory receives a usable sample. Liquid biopsy results are often available sooner. The risk of delay is real, and it is worth discussing with your oncologist before the test is ordered. In some situations — where one treatment is clearly appropriate regardless of result — your oncologist may start treatment and run testing in parallel. In others, the result genuinely determines which drug is given, and waiting is the safer choice. There is no universal answer; the conversation with your team is the place to make that call, not the laboratory turnaround estimate alone.

Coverage varies by scheme, state, and the specific test ordered. Ayushman Bharat PM-JAY covers some oncology diagnostics at empanelled hospitals, but the list of included tests and reimbursement limits change, and not every next-generation sequencing panel is included. Some state cancer schemes — including those in Telangana and Andhra Pradesh — cover selected biomarker tests at designated government cancer centres. Ask the hospital's insurance or billing desk specifically about molecular testing coverage before the test is ordered, and ask your oncologist whether a narrower targeted test — if covered — would answer the clinical question instead of a broader panel that is not.

A result with no new actionable alterations is still informative — it tells your oncologist that a molecularly guided option is unlikely to apply right now, and the decision moves to clinical and histological factors instead. It does not close every door: clinical trials sometimes enrol on the basis of mutation-negative status, and new approvals occur regularly. Your oncologist may recommend repeat testing again at a later point if the disease continues to change, or may suggest a different investigational approach. We do not yet have reliable ways to predict which patients will acquire actionable alterations at a later progression, but the field is evolving. A negative result is not the same as no options remaining.

Tell your oncologist directly and specifically — do not assume they know your financial situation, because the cost conversation rarely happens unless the patient raises it. Your oncologist may be able to order a narrower targeted test rather than a broad panel, one that answers the specific clinical question at lower cost. Some pharmaceutical companies run companion diagnostic programmes that cover testing for patients being considered for their drug. NGOs working in cancer care in Telangana and Andhra Pradesh sometimes subsidise diagnostic costs for families who qualify. Ask the social worker or patient coordinator at your centre what is available locally before deciding not to test at all.